


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR MARKETING OF “LOXOPROFEN SODIUM CATAPLASMS”

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Loxoprofen Sodium Cataplasms” (trade name: Deshuping (得舒平)) developed by the Group have obtained approval for marketing from the National Medical Products Administration of China. The product is used as an anti-inflammatory and analgesic in diseases and symptoms including osteoarthritis, muscle pain, and swelling and pain due to injuries. Deshuping is the only loxoprofen sodium cataplasm in China that has passed the Consistency Evaluation and been validated through clinical trials before being approved for marketing.

Loxoprofen sodium is a non-steroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class, which blocks prostaglandin synthesis by inhibiting the enzyme cyclooxygenase, thus achieving anti-inflammatory, antipyretic and analgesic effects. Compared with other NSAIDs, loxoprofen sodium is a prodrug that is safe and well tolerated. Its oral preparation has been widely used since its introduction in 1986.

As a leading manufacturer of modern topical/transdermal preparations in China, the Group leveraged its self-developed cataplasm technology platform and conducted a positive drug/placebo parallel controlled Phase III clinical trial for the development of Loxoprofen Sodium Cataplasms. In the clinical trial, the product showed remarkable efficacy, high safety and good skin compatibility. Compared with the oral preparation of loxoprofen sodium, the topical Loxoprofen Sodium Cataplasms can increase the local concentration of loxoprofen sodium at the pain site, thus avoiding the first-pass effect on the liver and improving its efficacy while avoiding gastrointestinal irritation. It also has long-lasting efficacy and is well tolerated. The once-daily dosing frequency can significantly improve patient compliance.

As another key cataplasm product of the Group after Flurbiprofen Cataplasms and Lidocaine Cataplasms, Loxoprofen Sodium Cataplasms have further strengthened the Group's product pipeline in surgery and analgesia. As the original Loxoprofen Sodium Cataplasms are currently not available in China, Deshuping will provide more treatment options for patients and ensure their medication safety.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 7 February 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.